Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dual Targeting of Human Epidermal Growth Factor Receptor 2 (HER2) in Neoadjuvant Trials for Operable HER2 Positive (HER2+) Disease

Dual Targeting of Human Epidermal Growth Factor Receptor 2 (HER2) in Neoadjuvant Trials for... The neoadjuvant strategy, initially developed to render primary inoperable tumors operable, is now increasingly being utilized for patients with triple-negative and HER2 positive breast cancer in clinical trials in order to assess for response and resistance with the incorporation of tissue biopsy studies. Pathological complete response (pCR) has been accepted as a primary endpoint in a number of neoadjuvant trials for operable HER2+ disease. This article provides a comprehensive summary of the knowledge gained from neoadjuvant trials conducted with HER2 directed agents to date, focuses on the concept of dual blockade of HER2, highlights the importance of predictive biomarkers, and finally puts them into perspective with current treatment recommendations and future research and trends. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Dual Targeting of Human Epidermal Growth Factor Receptor 2 (HER2) in Neoadjuvant Trials for Operable HER2 Positive (HER2+) Disease

Current Breast Cancer Reports , Volume 5 (4) – Nov 15, 2013

Loading next page...
 
/lp/springer-journals/dual-targeting-of-human-epidermal-growth-factor-receptor-2-her2-in-ke0GmbeIjt

References (66)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-013-0124-x
Publisher site
See Article on Publisher Site

Abstract

The neoadjuvant strategy, initially developed to render primary inoperable tumors operable, is now increasingly being utilized for patients with triple-negative and HER2 positive breast cancer in clinical trials in order to assess for response and resistance with the incorporation of tissue biopsy studies. Pathological complete response (pCR) has been accepted as a primary endpoint in a number of neoadjuvant trials for operable HER2+ disease. This article provides a comprehensive summary of the knowledge gained from neoadjuvant trials conducted with HER2 directed agents to date, focuses on the concept of dual blockade of HER2, highlights the importance of predictive biomarkers, and finally puts them into perspective with current treatment recommendations and future research and trends.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Nov 15, 2013

There are no references for this article.